Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 March;66(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 March;66(1):3-14

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  PET/MRI IN MUSCULOSKELETAL CONDITIONS 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2022 March;66(1):3-14

DOI: 10.23736/S1824-4785.21.03432-4

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Contribution of positron emission tomography/magnetic resonance imaging in musculoskeletal malignancies

Lina GARCÍA CAÑAMAQUE 1 , Caroline A. FIELD 1, Felipe S. FURTADO 2, Isabel PLAZA DE LAS HERAS 1, Jad S. HUSSEINI 2, Rene BALZA 2, Mohamed JARRAYA 2, Onofrio A. CATALANO 2, Merche MITJAVILA CASANOVAS 3

1 Department of Nuclear Medicine, Madrid Sanchinarro University Hospital, Madrid, Spain; 2 Department of Radiology, Massachusetts General Hospital, Boston, MA, USA; 3 Department of Nuclear Medicine, Puerta de Hierro Majadahonda University Hospital, Madrid, Spain



Positron emission tomography/computed tomography (PET/CT) is a promising hybrid imaging technique for evaluating musculoskeletal malignancies. Both technologies, independently are useful for evaluating this type of tumors. PET/MR has great potential combining metabolic and functional imaging PET with soft tissue contrast and multiparametric sequences of MR. In this paper we review the existing literature and discuss the different protocols, new available radiotracers to conclude with the scarce evidence available the most useful/probable indications of the PET MR for the for musculoskeletal malignancies.


KEY WORDS: Bone and bones; Neoplasm metastasis; Multiple myeloma; Sarcoma; Positron-emission tomography; Magnetic resonance imaging

top of page